384
Participants
Start Date
April 30, 2008
Primary Completion Date
June 30, 2009
Study Completion Date
June 30, 2009
Valsartan + HCTZ
At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
Valsartan
At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
HCTZ
At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal \<140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
Investigative site, Birmingham
Investigative site, Phoenix
Investigative Site, Escondido
Investigative site, Fresno
Investigative site, Huntington Park
Investigative Sites, Pismo Beach
Investigative site, Miami
Investigative site, Ormond Beach
Investigative site, Conyers
Investigative Site, Lexington
Investigative site, Portland
Investigative site, Las Vegas
Investigative site, Buffalo
Investigative site, Shelby
Investigative site, Carlisle
Investigative site, Oklahoma City
Investigative site, Erie
Investigative Site, Greer
Investigative Site, Taylors
Investigative site, St. George
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY